Speciality: Nephrology
Description:
A warm welcome to all the medical professionals in this exciting session on evolving science in the space of CKD.
The global prevalence of CKD is substantial with profound implications, healthcare costs, and outcomes. The risk of morbidity and mortality rises sharply as CKD progresses. The vast majority of larger-scale trials in CKD have focussed on Type 2 Diabetes populations.
SGLT2 inhibition has a number of potential direct and downstream effects which may result in beneficial effects on kidney function. SGLT2i CVOTs have consistently shown a reduction in renal endpoints. DAPA-CKD builds upon the evidence for Dapagliflozin in preventing hHF and worsening renal disease in DECLARE and reducing the risk of worsening HF and CV death in DAPA-HF.
Therefore, listen to the webinar, grab the shared knowledge, and follow HiDoc for more such exciting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation